Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation
Albany, NY (PRWEB) January 30, 2014
The Systemic Lupus Erythematosus (SLE) drug market is currently under-served by non-generic, targeted therapies. Whilst the only Food and Drug Administration (FDA)-approved biologic, Benlysta (belimumab), generated sales of $111m in 2012, there is little evidence that the drug’s performance is significantly superior to other B-cell targeted therapies such as Rituxan (rituximab), which is often used off-license to treat refractory SLE patients.
Therapeutics entering the market therefore do not face the staggering level of competition from currently marketed programs as in other markets such as the Rheumatoid Arthritis (RA) market. Emerging market entrants that appear to offer significant therapeutic benefits are likely to cause dramatic changes to the market landscape.
A growing understanding of the signaling pathways underlying SLE pathophysiology including, but not limited to, B cells, T cells and intracellular kinases, is translating into a higher number of novel, and more importantly, first-in-class targeted therapeutics entering the developmental pipeline. In particular, a high level of investment in the development of cytokine-blocking strategies is evident, as therapies targeting the interferon pathway are relatively common in the pipeline.
Browse All Latest Market Research Report @ http://www.researchmoz.us/latest-report.html.
The report analyzes the market for SLE therapeutics and the pipeline products in that market, with particular emphasis on first-in-class programs.
A brief introduction to SLE, including symptoms, pathophysiology, disease scoring indices and overview of pharmacotherapy
In-depth analysis and literature review on marketed products, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses, based on published clinical trials, as well as a reference table of drugs in terms of safety and efficacy
Overview of how innovation products are contributing to the market for SLE therapeutics
Comprehensive review of the pipeline for first-in-class therapies, which is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes
The changing molecular target landscape between market and pipeline, and, in particular, focal points of innovation
First-in-class molecular targets, highlighting early-stage programs for which clinical utility has yet to be evaluated, as well as an in-depth literature review on novel molecular targets
All GBI Market Research Report @ http://www.researchmoz.us/publisher/gbi-research-2.html.
Reasons to buy
The report will assist the business development strategies of companies that wish to develop novel therapies with improved benefits to existing treatments. It will also be of interest to companies seeking to expand their pipeline portfolio through licensing agreements and co-development deals. Primarily, the report will allow clients to identify and understand market opportunities and the emerging competitive environment. It will also allow you to
Understand the SLE pipeline and the factors which indicate that it is becoming more innovative
Understand the overall focal shifts in therapeutic molecular targets for the treatment of SLE
Understand the distribution of the pipeline programs by phase of development, molecule type and molecular target
Identify the list of first-in-class programs that are potentially open to deal-making opportunities
Understand the first-in-class developmental programs and gauge the current clinical effectiveness based on animal models
Personalized Medicine in Oncology
The Personalized Medicine(http://www.researchmoz.us/personalized-medicine-in-oncology-partnering-terms-and-agreements-report.html) in Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Insulin Pump Market & Forecast
Insulin Pumps(http://www.researchmoz.us/insulin-pump-market-and-forecast-worldwide-analysis-report.html) are gaining strong acceptance in the market as insulin delivery systems especially for type 1 diabetes patients. Insulin pumps are gaining a lot of attraction in United States and European countries. But due to high costs of insulin pumps it has still not able to penetrate successfully in emerging markets. If insulin pump cost declines then its market is expected to grow immensely. Number of insulin pump users is expected to grow with single digit CAGR for the period of 2013 to 2018.
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis.We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports.We provide our services to all sizes of organizations and across all industry verticals and markets.Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948